Antiproliferative and apoptotic activities of tosylcyclonovobiocic acids as potent heat shock protein 90 inhibitors in human cancer cells

Cancer Letters

Volumn 274, Issue 1, 2009, Pages 88-94

  Radanyi, Christine ^a   Bras, Gaëlle Le ^a   Marsaud, Véronique ^a   Peyrat, Jean François ^a   Messaoudi, Samir ^a   Catelli, Maria Grazia ^b   Brion, Jean Daniel ^a   Alami, Mouâd ^a   Renoir, Jack Michel ^a  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b INSERM   (France)

Author keywords

Apoptosis; Cell cycle arrest; Coumarins; hsp90 inhibitors; Novobiocin

Indexed keywords

4 TOSYLCYCLONOVOBIOCIC ACID; 7 TOSYLCYCLONOVOBIOCIC ACID; ANTINEOPLASTIC AGENT; CASPASE 3; CASPASE 7; CASPASE 8; CASPASE 9; CYCLIN DEPENDENT KINASE 4; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NOVOBIOCIN; RAF PROTEIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BREAST ADENOCARCINOMA; CANCER CELL; CANCER CELL CULTURE; CANCER THERAPY; CELL DEATH; CELL STRAIN HT29; COLON ADENOCARCINOMA; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG INHIBITION; ENDOMETRIUM CARCINOMA; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; ONCOGENESIS AND MALIGNANT TRANSFORMATION; OVARY CANCER; PRIORITY JOURNAL; PROTEIN FUNCTION;

EID: 57849109385     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2008.09.001     Document Type: Article

References (34)

1. Pratt W.B., and Toft D.O. Regulation of signaling protein function and trafficking by the hsp90/hsp70-based chaperone machinery. Exp. Biol. Med. 228 (2003) 111-133
2. Richter K., and Buchner J. Hsp90: chaperoning signal transduction. J. Cell. Physiol. 188 (2001) 281-290
3. Neckers L. Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol. Med. 8 (2002) S55-S61
4. Maloney A., and Workman P. HSP90 as a new therapeutic target for cancer therapy: the story unfolds. Expert Opin. Biol. Ther. 2 (2002) 3-24
5. Zhang H., and Burrows F. Targeting multiple signal transduction pathways through inhibition of Hsp90. J. Mol. Med. 82 (2004) 488-499
6. Panaretou B., Prodromou C., Roe S.M., O'Brien R., Ladbury J.E., Piper P.W., and Pearl L.H. ATP binding and hydrolysis are essential to the function of the Hsp90 molecular chaperone in vivo. EMBO J. 17 (1998) 4829-4836
7. Grenert J.P., Johnson B.D., and Toft D.O. The importance of ATP binding and hydrolysis by Hsp90 in formation and function of protein heterocomplexes. J. Biol. Chem. 274 (1999) 17525-17533
8. An W.G., Schnur R.C., Neckers L., and Blagosklonny M.V. Depletion of p185erbB2, Raf-1 and mutant p53 proteins by geldanamycin derivatives correlates with antiproliferative activity. Cancer Chemother. Pharmacol. 40 (1997) 60-64
9. Blagosklonny M.V. Hsp-90-associated oncoproteins: multiple targets of geldanamycin and its analogs. Leukemia 16 (2002) 455-462
10. Kelland L.R., Sharp S.Y., Rogers P.M., Myers T.G., and Workman P. DT-diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90. J. Natl. Cancer Inst. 91 (1999) 1940-1949
11. Roe S.M., Prodromou C., O'Brien R., Ladbury J.E., Piper P.W., and Pearl L.H. Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin. J. Med. Chem. 42 (1999) 260-266
12. Chiosis G. Discovery and development of purine-scaffold Hsp90 inhibitors. Curr. Top. Med. Chem. 6 (2006) 1183-1191
13. Marcu M.G., Chadli A., Bouhouche I., Catelli M., and Neckers L.M. The heat shock protein 90 antagonist novobiocin interacts with a previously unrecognized ATP-binding domain in the carboxyl terminus of the chaperone. J. Biol. Chem. 275 (2000) 37181-37186
14. Söti C., Ràcz A., and Csermely P. A nucleotide-dependent molecular switch controls ATP binding at the C-terminal domain of Hsp90: N-terminal nucleotide binding unmasks a C-terminal binding pocket. J. Biol. Chem. 277 (2002) 7066-7075
15. Marcu M.G., Schulte T.W., and Neckers L. Novobiocin and related coumarins and depletion of heat shock protein 90-dependent signaling proteins. J. Natl. Cancer Inst. 92 (2000) 242-248
16. Yu X.M., Shen G., Neckers L., Blake H., Holzbeierlein J., Cronk B., and Blagg B.S.J. Hsp90 inhibitors identified from a library of novobiocin analogues. J. Am. Chem. Soc. 127 (2005) 12778-12779
17. Burlison J.A., Neckers L., Smith A.B., Maxwell A., and Blagg B.S.J. Novobiocin: redesigning a DNA gyrase inhibitor for selective inhibition of Hsp90. J. Am. Chem. Soc. 128 (2006) 15529-15536
18. Le Bras G., Radanyi C., Peyrat J.-F., Brion J.-D., Alami M., Marsaud V., Stella B., and Renoir J.-M. New novobiocin analogues as antiproliferative agents in breast cancer cells and potential inhibitors of heat shock protein 90. J. Med. Chem. 50 (2007) 6189-6200
19. Wellbrock C., Karasarides M., and Marais R. The Raf proteins take centre stage. Nat. Rev. Mol. Cell Biol. 5 (2004) 875-885
20. Vogel C.L., Cobleigh M.A., Tripathy D., Gutheil J.C., Harris L.N., Fehrenbacher L., Slamon D.J., Murphy M., Novotny W.F., Burchmore M., Shak S.S., Stewart S.J., and Press M. Efficacy and safety of Trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol. 20 (2002) 719-726
21. Nicholson R.I., Hutcheson I.R., Hiscox S.E., Knowlden J.M., Giles M., Barrow D., and Gee J.M.W. Growth factor signalling and resistance to selective oestrogen receptor modulators and pure anti-oestrogens: the use of anti-growth factor therapies to treat or delay endocrine resistance in breast cancer. Endocr. Relat. Cancer 12 (2005) S29-S36
22. Basso A.D., Solit D.B., Munster P.N., and Rosen N. Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2. Oncogene 21 (2002) 1159-1166
23. Jascur T., Brickner H., Salles-Passador I., Barbier V., El Khissiin A., Smith B., Fotedar R., and Fotedar A. Regulation of p21WAF1/CIP1 stability by WISp39, a Hsp90 binding TPR protein. Mol. Cell 17 (2005) 237-249
24. Hostein I., Robertson D., DiStefano F., Workman P., and Clarke P.A. Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin results in cytostasis and apoptosis. Cancer Res. 61 (2001) 4003-4009
25. Bratton S.B., MacFarlane M., Cain K., and Cohen G.M. Protein complexes activate distinct caspase cascades in death receptor and stress-induced apoptosis. Exp. Cell Res. 256 (2000) 27-33
26. Hickman J.A. Apoptosis and tumourigenesis. Curr. Opin. Genet. Dev. 12 (2002) 67-72
27. Raymond E., Faivre S., Chaney S., Woynarowski J., and Cvitkovic E. Cellular and molecular pharmacology of oxaliplatin. Mol. Cancer Ther. 1 (2002) 227-235
28. Holland C. Endometrial cancer. Obst. Gyn. Reprod. Med. 17 (2007) 318-323
29. Nowak A.K., Chow P.K.H., and Findlay M. Systemic therapy for advanced hepatocellular carcinoma: a review. Eur. J. Cancer 40 (2004) 1474-1484
30. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 (2000) 57-70
31. Neckers L. Heat shock protein 90: the cancer chaperone. J. Biosci. 32 (2007) 517-530
32. Hadden M.K., Galam L., Gestwicki J.E., Matts R.L., and Blagg B.S.J. Derrubone, an inhibitor of the Hsp90 folding machinery. J. Nat. Prod. 70 (2007) 2014-2018
33. Tash J.S., Chakrasali R., Jakkaraj S.R., Hugues J., Smith S.K., Hornbaker K., Heckert L.L., Ozturk S.B., Hadden M.K., Kinzy T.G., Blagg B.S.J., and Georg G.I. Gamendazole, an orally active indazole carboxylic acid male contraceptive agent, targets HSP90AB1 (HSP90BETA) and EEF1A1 (eEF1A), and stimulates II1a transcription in rat Sertoli cells. Biol. Reprod. 78 (2008) 1139-1152
34. Radanyi C., Le Bras G., Messaoudi S., Bouclier C., Peyrat J.-F., Brion J.-D., Marsaud V., Renoir J.-M., and Alami M. Synthesis and biological activity of simplified denoviose-coumarins related to novobiocin as potent inhibitors of heat-shock protein 90 (hsp90). Bioorg. Med. Chem. Lett. 18 (2008) 2495-2498